ArriVent BioPharma (AVBP) Enterprise Value (2023 - 2026)

ArriVent BioPharma has disclosed Enterprise Value across 4 years of filings, most recently posting -$590.7 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$590.7 million, down 78.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$590.7 million (down 78.07% YoY), and the FY2025 annual result was -$312.8 million, down 46.27% from the prior year.
• Enterprise Value came in at -$590.7 million for Q1 2026 at ArriVent BioPharma, down from -$312.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$124.3 million in Q4 2023 to a low of -$590.7 million in Q1 2026.
• The 4-year median for Enterprise Value is -$299.5 million (2024), against an average of -$300.8 million.
• Across the five-year window, Enterprise Value rose 21.09% in 2025 and sank 78.07% in 2026, its largest moves.
• ArriVent BioPharma's Enterprise Value stood at -$124.3 million in 2023, then plunged by 72.06% to -$213.9 million in 2024, then sank by 46.27% to -$312.8 million in 2025, then slumped by 88.82% to -$590.7 million in 2026.
• The last three Enterprise Value figures came in at -$590.7 million (Q1 2026), -$312.8 million (Q4 2025), and -$300.3 million (Q3 2025), per Business Quant data.